Ranibizumab Intravitreal Injection-Monotherapy-Treatment for Retinopathy of Prematurity in Iraq

Mahmood, Ali Abdul Razzaq Al Mafrachi; Hussein, Zaid Rajab; Yasir, Muthanna Basheer; Kaptan, Suzan Abdul Muhsin; Ameri, Ammar Abdul Razzaq Abood Al; AlHasseny, Khitam Fahkir

doi:10.4172/2155-9570.1000735

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В целом положительный результат (регресс ретинопатии и завершение васкуляризации сетчатки) был получен у 98,2-100% пациентов. Осложнений местного или системного характера ни в одном исследовании отмечено не было [32][33][34][35][36][37].…”

Section: анти-Vegf терапия при заболеваниях сетчаткиunclassified

Vascular endothelial growth factor inhibitors for retinopathy of prematurity

Zhukova¹,

Maltseva²,

Золотарев³

2020

Russian Journal of Clinical Ophthalmology

View full text Add to dashboard Cite

The article addresses current treatment modalities for threshold retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP), in particular, intravitreal administration of vascular endothelial growth factor (VEGF) inhibitors. The results of multicenter clinical trials evaluating pegaptanib, bevacizumab, and ranibizumab are discussed. The clinical effect of intravitreal anti-VEGF drugs was compared to the efficacy of laser retinal photocoagulation. In children with ROP, anti-VEGF drugs are equal or even superior to the conventional laser retinal photocoagulation in terms of clinical efficacy. No negative effects of anti-VEGF drugs on ocular tissues or vasculature development in premature children were demonstrated. Moreover, several studies show the potential efficacy of intravitreal anti-VEGF drugs plus avascular zone photocoagulation for APROP. Finally, our experience with intravitreal ranibizumab for threshold ROP and plus disease in a patient who was followed-up for subsequent 9 years is described.Keywords: retinopathy of prematurity, plus disease, aggressive posterior retinopathy of prematurity, anti-VEGF drugs, ranibizumab.For citation: Zhukova O.V., Mal’tseva I.A., Zolotarev A.V. Vascular endothelial growth factor inhibitors for retinopathy of prematurity. Russian Journal of Clinical Ophthalmology. 2020;20(4):216–220. DOI: 10.32364/2311-7729-2020-20-4-216-220.

show abstract